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BACKGROUND
Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive 
T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) 
blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL 
on the basis of single-group trials that showed efficacy and manageable toxic effects.
METHODS
In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pre-
treated B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standard-
of-care chemotherapy. The primary end point was overall survival.
RESULTS
Of the 405 patients who were randomly assigned to receive blinatumomab (271 patients) 
or chemotherapy (134 patients), 376 patients received at least one dose. Overall survival was 
significantly longer in the blinatumomab group than in the chemotherapy group. The 
median overall survival was 7.7 months in the blinatumomab group and 4.0 months in the 
chemotherapy group (hazard ratio for death with blinatumomab vs. chemotherapy, 0.71; 
95% confidence interval [CI], 0.55 to 0.93; P = 0.01). Remission rates within 12 weeks after 
treatment initiation were significantly higher in the blinatumomab group than in the che-
motherapy group, both with respect to complete remission with full hematologic recovery 
(34% vs. 16%, P<0.001) and with respect to complete remission with full, partial, or incom-
plete hematologic recovery (44% vs. 25%, P<0.001). Treatment with blinatumomab resulted 
in a higher rate of event-free survival than that with chemotherapy (6-month estimates, 31% 
vs. 12%; hazard ratio for an event of relapse after achieving a complete remission with full, 
partial, or incomplete hematologic recovery, or death, 0.55; 95% CI, 0.43 to 0.71; P<0.001), 
as well as a longer median duration of remission (7.3 vs. 4.6 months). A total of 24% of the 
patients in each treatment group underwent allogeneic stem-cell transplantation. Adverse 
events of grade 3 or higher were reported in 87% of the patients in the blinatumomab 
group and in 92% of the patients in the chemotherapy group.
CONCLUSIONS
Treatment with blinatumomab resulted in significantly longer overall survival than che-
motherapy among adult patients with relapsed or refractory B-cell precursor ALL. (Funded 
by Amgen; TOWER ClinicalTrials.gov number, NCT02013167.)
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The prognosis for adults with newly diagnosed acute lymphoblastic leukemia (ALL) has improved over the past three 
decades. With the use of intensive chemotherapy 
regimens, complete remission rates are 85 to 90% 
and long-term survival rates are 30 to 50%.1-4 
Still, most adults with B-cell precursor ALL will 
have a relapse and will die from complications of 
resistant disease or associated treatment. Among 
adults with relapsed or refractory ALL, remission 
rates are 18 to 44% with the use of standard 
salvage chemotherapy, but the duration of remis-
sion is typically short.5-10 A major goal in this 
population is to induce remission with sufficient 
duration to prepare for stem-cell transplantation.11 
The median overall survival among patients with 
relapsed or refractory ALL ranges from 2 to 
6 months, and 3-to-5-year survival rates are less 
than 10%.7-10,12 More effective treatment is need-
ed for relapsed and refractory ALL in adults.
The B-lineage surface antigen CD-19 is ex-
pressed on the surface of more than 90% of 
B-cell precursor ALL blasts.13 Blinatumomab 
(Blincyto, Amgen) is a bispecific T-cell engager 
antibody construct. Blinatumomab binds simul-
taneously to CD3-positive cytotoxic T cells and to 
CD19-positive B cells, which allows the patient’s 
endogenous T cells to recognize and eliminate 
CD19-positive ALL blasts.14-16
Single-group trials have shown the efficacy 
and safety of blinatumomab in the treatment 
of heavily pretreated Philadelphia chromosome 
(Ph)–negative relapsed or refractory B-cell pre-
cursor ALL.17,18 In a pivotal, multicenter, single-
group, phase 2 trial of blinatumomab, the rate 
of complete remission with complete or partial 
hematologic recovery was 43%, and the median 
overall survival was 6.1 months.18 We report here 
the results of a multinational, randomized, 
phase 3 trial that compared blinatumomab with 
standard chemotherapy in the treatment of pa-
tients with relapsed or refractory ALL.
Me thods
Trial Design
In this prospective, randomized, phase 3 trial, 
investigators at 101 centers in 21 countries en-
rolled adults (18 years of age or older) with 
Ph-negative B-cell precursor ALL in any of the 
following stages: refractory to primary induction 
therapy or to salvage with intensive combination 
chemotherapy, first relapse with the first remis-
sion lasting less than 12 months, second or 
greater relapse, or relapse at any time after allo-
geneic stem-cell transplantation. Additional eli-
gibility criteria included more than 5% blasts in 
the bone marrow and an Eastern Cooperative 
Oncology Group performance status of 2 or less 
(on a 5-point scale, with higher numbers indi-
cating greater disability). Key exclusion criteria 
were other active cancers, a clinically relevant 
pathologic condition of the central nervous sys-
tem, isolated extramedullary disease, autoimmune 
disease, acute graft-versus-host disease (GVHD) 
of grade 2 or higher or active chronic GVHD, 
allogeneic stem-cell transplantation within 12 
weeks before randomization, autologous stem-
cell transplantation within 6 weeks before ran-
domization, chemotherapy or radiotherapy within 
2 weeks before randomization, use of immuno-
therapy within 4 weeks before randomization, or 
ongoing use of investigational treatment.
Trial Oversight
All patients provided written informed consent. 
The trial was designed by Amgen in collabora-
tion with the trial investigators. The trial protocol 
(including the statistical analysis plan), which 
is available with the full text of this article at 
NEJM.org, was approved by the investigational 
review board or independent ethics committee at 
each trial center. The first two authors and the 
last author prepared the first draft of the manu-
script, with assistance from professional medi-
cal writers who were funded by Amgen. All the 
authors contributed revisions and had access to 
the data. All the authors vouch for the integrity 
and completeness of the data and for the fidelity 
of the trial to the protocol. Two authors who are 
employees of Amgen conducted the statistical 
analyses and contributed to the manuscript. An 
independent data and safety monitoring com-
mittee consisting of two clinicians and one bio-
statistician met regularly to review safety and 
efficacy data, which were provided by an inde-
pendent statistician.
Treatments
Eligible patients were randomly assigned, in a 
2:1 ratio, with the use of an interactive voice-
response system to receive open-label treatment 
with either blinatumomab or standard chemo-
therapy (Fig. S1 in the Supplementary Appendix, 
available at NEJM.org). Randomization was strat-
ified according to age (<35 vs. ≥35 years), previ-
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ous salvage therapy (yes vs. no), and previous 
allogeneic stem-cell transplantation (yes vs. no). 
Patients in each treatment group were to receive 
up to two cycles of induction therapy; in addi-
tion, in each group, patients in morphologic re-
mission (≤5% bone marrow blasts) were to re-
ceive up to three cycles of consolidation therapy, 
and patients in continued morphologic remis-
sion were to receive up to 12 months of main-
tenance therapy.
Induction and consolidation treatments with 
blinatumomab were administered in 6-week cy-
cles; in each cycle, patients received treatment for 
4 weeks (9 μg per day during week 1 of induc-
tion cycle 1 and 28 μg per day thereafter, by con-
tinuous infusion) and no treatment for 2 weeks. 
Maintenance treatment with blinatumomab was 
given as a 4-week continuous infusion every 12 
weeks. Patients in the blinatumomab group who 
had high tumor load during screening were to 
receive dexamethasone before the start of treat-
ment to prevent the cytokine release syndrome 
(Table S1 in the Supplementary Appendix). All 
patients in the blinatumomab group were to re-
ceive dexamethasone before their dose of blina-
tumomab to prevent infusion reactions (Table S1 
in the Supplementary Appendix) and were to re-
ceive intrathecal prophylaxis for central nervous 
system disease according to institutional or na-
tional guidelines. Interruption or discontinuation 
of the dose of blinatumomab was required if 
neurologic events or other selected adverse events 
occurred (further details are provided in the 
Dose Modification section in the Supplementary 
Appendix); dose adjustment was permitted for 
patients receiving standard chemotherapy but was 
not required for specific events. Patients in the 
chemotherapy group received the investigator’s 
choice of one of the following four regimens: 
fludarabine, high-dose cytosine arabinoside, and 
granulocyte colony-stimulating factor with or with-
out anthracycline; a high-dose cytosine arabino-
side–based regimen; a high-dose methotrexate-
based regimen; or a clofarabine-based regimen 
(Table S2 in the Supplementary Appendix). Proto-
col-specified therapy could be discontinued at 
any time after the first treatment cycle and the 
patient could subsequently undergo stem-cell 
transplantation if the investigator determined 
that such actions were in the patient’s best 
 interest.
Assessments
Complete remission was defined as 5% or less 
bone marrow blasts and no evidence of disease 
and was further characterized according to the 
extent of recovery of peripheral blood counts as 
follows: complete remission with full recovery 
(platelet count of >100,000 per microliter and 
absolute neutrophil count of >1000 per microli-
ter), complete remission with partial recovery 
(platelet count of >50,000 per microliter and 
absolute neutrophil count of >500 per microli-
ter), or complete remission with incomplete re-
covery (platelet count of >100,000 per microliter 
or absolute neutrophil count of >1000 per micro-
liter). Minimal residual disease was assessed at 
one central laboratory for trial centers in the 
United States and Canada (64 patients) with the 
use of multicolor flow cytometry and at another 
central laboratory for other trial centers (341 
patients) with the use of real-time quantitative 
polymerase chain reaction of clonal immuno-
globulin or T-cell receptor gene rearrangements 
with an assay sensitivity of at least 0.0001.19,20 
Lumbar puncture was performed during each 
cycle to evaluate leukemic involvement of the 
central nervous system. Adverse events were 
graded according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse 
Events (CTCAE), version 4.0. Serious adverse 
events included events that were fatal or life-
threatening, required or prolonged hospitaliza-
tion, resulted in disability or incapacity, or re-
sulted in a congenital anomaly or birth defect or 
were other medically important serious events 
such as an overdose. Adverse events of interest 
were identified by a steering committee.
Statistical Analysis
The primary end point was overall survival, 
which was defined as the time from randomiza-
tion to death from any cause. Key secondary end 
points included achievement of complete remis-
sion with full hematologic recovery within 12 
weeks after initiation of treatment; achievement 
of complete remission with full, partial, or in-
complete hematologic recovery within 12 weeks 
after initiation of treatment; and event-free sur-
vival (defined as the time from randomization 
until relapse after achieving a complete remis-
sion with full, partial, or incomplete hemato-
logic recovery, or death). Other secondary end 
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points included the duration of complete remis-
sion, minimal residual disease remission (de-
fined as a minimal residual disease level below 
0.0001), the rate of allogeneic stem-cell trans-
plantation, and adverse event rates. Final results 
for key secondary end points were to be tested 
in a hierarchical manner if the results of the 
primary end point were found to be significant. 
We calculated that an enrollment target of 400 
patients and a total of approximately 330 deaths 
would give the trial approximately 85% power to 
detect a hazard ratio for death of 0.70 in the 
blinatumomab group as compared with chemo-
therapy at a two-sided alpha level of 0.05; this 
calculation was based on an assumed median 
overall survival of 4.2 months in the chemo-
therapy group8,9 and a 10% dropout rate. Two 
interim analyses were planned to assess a sur-
vival benefit when 50% and 75% of the planned 
deaths for the final analysis had been observed. 
The O’Brien–Fleming stopping boundary at the 
time of each interim analysis was calculated 
with the use of a Lan–DeMets alpha-spending 
function.21,22
Efficacy analyses included all patients who 
underwent randomization (intention-to-treat 
population). Safety analyses and efficacy sensi-
tivity analyses included all patients who received 
at least one dose of trial treatment (as-treated 
population). Time-to-event estimates were calcu-
lated with the use of the Kaplan–Meier method, 
and treatment groups were compared by means 
of two-sided stratified log-rank tests. The treat-
ment effect was expressed as a hazard ratio with 
a 95% confidence interval, which was estimated 
with the use of a stratified Cox regression 
model. Remission rates were compared with the 
use of a stratified two-sided Cochran–Mantel–
Haenszel test.
R esult s
Trial Population and Treatment
Patients were enrolled from January 2014 
through September 2015. After 75% of the total 
number of planned deaths for the final analysis 
had occurred, the independent data and safety 
monitoring committee recommended that the 
trial be stopped early because of benefit ob-
served with blinatumomab therapy. The data 
cutoff date was January 4, 2016. Of the 405 pa-
tients who underwent randomization, 376 re-
ceived open-label trial treatment (267 of 271 
patients [99%] received blinatumomab and 109 
of 134 patients [81%] received standard chemo-
therapy); less than 1% of the 271 patients in the 
blinatumomab group and 16% of the 134 pa-
tients in the chemotherapy group withdrew 
consent before receiving treatment (Fig. S2 in 
the Supplementary Appendix). A total of 22 pa-
tients (8%) in the blinatumomab group and no 
patients in the chemotherapy group were con-
tinuing trial treatment at the time of the analy-
sis. The chemotherapy regimen was fludarabine, 
high-dose cytosine arabinoside, and granulocyte 
colony-stimulating factor with or without an-
thracycline for 49 patients (45%); a high-dose 
cytosine arabinoside–based regimen for 19 pa-
tients (17%); a high-dose methotrexate-based 
regimen for 22 patients (20%); and a clofara-
bine-based regimen for 19 patients (17%). The 
two treatment groups had similar demographic 
and disease characteristics at baseline when all 
patients who underwent randomization were 
assessed (Table 1) as well when patients who did 
not receive the trial treatment were excluded 
(Table S3 in the Supplementary Appendix).
The median number of treatment cycles was 
2 (range, 1 to 9) in the blinatumomab group and 
1 (range, 1 to 4) in the chemotherapy group. 
Consolidation therapy with trial treatment was 
administered to 32% of treated patients in the 
blinatumomab group and to 3% of treated pa-
tients in the chemotherapy group.
Overall Survival
For this prespecified interim analysis, 251 deaths 
were recorded. Overall survival was significantly 
longer in the blinatumomab group than in the 
chemotherapy group. The median overall sur-
vival was 7.7 months (95% confidence interval 
[CI], 5.6 to 9.6) in the blinatumomab group ver-
sus 4.0 months (95% CI, 2.9 to 5.3) in the che-
motherapy group (hazard ratio for death, 0.71; 
95% CI, 0.55 to 0.93; P = 0.01, which crossed the 
prespecified stopping boundary) (Fig. 1A), with 
a median duration of follow-up of 11.7 and 11.8 
months, respectively. Overall survival curves for 
the blinatumomab and chemotherapy groups 
separated within 3 months and converged again 
between 15 and 18 months. Similar results were 
seen after exclusion of the data from patients 
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Characteristic
Blinatumomab Group 
(N = 271)
Chemotherapy Group 
(N = 134)
Age — yr
Mean 40.8 ± 17.1 41.1 ± 17.3
Range 18–80 18–78
Male sex — no. (%) 162 (59.8) 77 (57.5)
Race — no. (%)†
White 228 (84.1) 112 (83.6)
Asian 19 (7.0) 9 (6.7)
Black 5 (1.8) 3 (2.2)
Other 19 (7.0) 10 (7.5)
Hispanic ethnic group — no. (%) 26 (9.6) 11 (8.2)
Geographic region — no. (%)
Europe 180 (66.4) 85 (63.4)
United States or Canada 41 (15.1) 23 (17.2)
Rest of world 50 (18.5) 26 (19.4)
ECOG performance status — no. (%)‡
0 96 (35.4) 52 (38.8)
1 134 (49.4) 61 (45.5)
2 41 (15.1) 20 (14.9)
Missing data 0 1 (0.7)
Key trial inclusion criteria — no. (%)
Disease refractory to primary therapy or salvage therapy 115 (42.4) 54 (40.3)
First relapse, with duration of first remission <12 mo 76 (28.0) 37 (27.6)
Untreated second or greater relapse§ 32 (11.8) 16 (11.9)
Relapse after allogeneic stem‑cell transplantation§ 46 (17.0) 27 (20.1)
Not specified 2 (0.7) 0
Previous allogeneic stem‑cell transplantation — no. (%)
Yes 94 (34.7) 46 (34.3)
No 176 (64.9) 87 (64.9)
Unknown 1 (0.4) 1 (0.7)
Salvage‑treatment phase — no. (%)
First 114 (42.1) 65 (48.5)
Second 91 (33.6) 43 (32.1)
Third 45 (16.6) 16 (11.9)
Fourth 14 (5.2) 5 (3.7)
Fifth or later 7 (2.6) 5 (3.7)
Maximum central or local bone marrow blasts — no. (%)
>5 to <10% 9 (3.3) 7 (5.2)
10 to <50% 60 (22.1) 23 (17.2)
≥50% 201 (74.2) 104 (77.6)
Unknown 1 (0.4) 0
Peripheral blast count in blood (x 10−9/liter) 4.4 ± 15.5 5.0 ± 15.7
*  Plus–minus values are means ±SD. There were no significant between‑group differences in the characteristics evaluated at baseline. A com‑
plete summary of disease characteristics at baseline is provided in Table S3 in the Supplementary Appendix. Data are summarized for all 
patients who underwent randomization (intention‑to‑treat population). Percentages may not total 100 because of rounding.
†  Race was determined by the investigator.
‡  The Eastern Cooperative Oncology Group (ECOG) performance status scale ranges from 0 to 5, with higher numbers indicating greater dis‑
ability.
§  Patients who met this inclusion criterion met none of the above inclusion criteria.
Table 1. Demographic and Baseline Clinical Characteristics of the Patients.*
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who did not receive trial treatment (Fig. S3 in 
the Supplementary Appendix). When data were 
censored at the time of allogeneic stem-cell 
transplantation, the median overall survival was 
6.9 months (95% CI, 5.3 to 8.8) in the blinatu-
momab group and 3.9 months (95% CI, 2.8 to 
4.9) in the chemotherapy group (hazard ratio for 
death, 0.66; 95% CI, 0.50 to 0.88; P = 0.004) 
(Fig. 1B). The transplantation-censored overall 
survival curves for the blinatumomab and che-
motherapy groups separated within 3 months 
and did not converge again. Estimated survival 
at 6 months among all patients who underwent 
randomization was 54% in the blinatumomab 
group and 39% in the chemotherapy group. The 
treatment benefit with respect to overall survival 
was generally consistent across key subgroups 
(Fig. 2A).
Remission Rates
Remission rates within 12 weeks after treatment 
initiation were significantly higher in the blina-
tumomab group than in the chemotherapy group 
with respect to complete remission with full 
hematologic recovery (CR, 34% vs. 16%; P<0.001) 
and with respect to complete remission with full, 
partial, or incomplete hematologic recovery (CR, 
CRh, or CRi, 44% vs. 25%; P<0.001) (Table 2). 
Remission rates consistently favored blinatumo-
mab over chemotherapy across key subgroups 
(Fig. 2B). Among the patients who had complete 
Figure 1. Efficacy End Points.
Panel A shows the probability of overall survival in the 
two groups. Overall survival was calculated as the time 
from randomization to death from any cause. The me‑
dian duration of follow‑up for overall survival was 11.7 
months in the blinatumomab group and 11.8 months 
in the chemotherapy group. Panel B shows the proba‑
bility of overall survival in the two groups (also calcu‑
lated as the time from randomization to death from any 
cause) when data were censored at the time of allogeneic 
stem‑cell transplantation. The median duration of follow‑
up for this analysis of overall survival was 7.0 months 
in the blinatumomab group and 6.0 months in the che‑
motherapy group. Panel C shows the probability of event‑
free survival, which was calculated as the time from 
randomization until relapse after complete remission 
with full, partial, or incomplete hematologic recovery, 
or death; patients who did not achieve a complete re‑
mission with full, partial, or incomplete hematologic 
recovery were assigned an event‑free duration of 1 day. 
The median duration of follow‑up for event‑free sur‑
vival was 7.8 months in the blinatumomab group and 
10.2 months in the chemotherapy group. All three 
analyses were performed in the intention‑to‑treat popu‑
lation. P values were determined by means of stratified 
log‑rank tests.
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remission with full, partial, or incomplete hema-
tologic recovery, 76% of the patients in the blina-
tumomab group and 48% in the chemotherapy 
group achieved a negative status (i.e., remission) 
for minimal residual disease (treatment differ-
ence, 28 percentage points; 95% CI, 9 to 47).
Event-free Survival and Duration  
of Remission
Among the patients who had complete remis-
sion with full, partial, or incomplete hemato-
logic recovery, the median duration of remission 
was 7.3 months (95% CI, 5.8 to 9.9) in the blina-
Figure 2. Subgroup Analyses.
Panel A shows the results of an analysis of overall survival in prespecified subgroups of the intention‑to‑treat population that were 
 defined according to baseline characteristics. Overall survival was calculated as the time from randomization to death from any cause. 
Panel B shows the results of an analysis of remission rates in prespecified subgroups of the intention‑to‑treat population that were de‑
fined according to baseline characteristics. The remission rate was defined as the percentage of patients who had complete hematologic 
remission with full, partial, or incomplete hematologic recovery by week 12. For both analyses, bone marrow blast data were from the 
central laboratory, if available; otherwise, data from the local laboratory were used. Central and local baseline results for bone marrow 
blasts were missing for one patient in the blinatumomab group.
10.0
Chemotherapy
Better
Blinatumomab
Better
Age
<35 yr
≥35 yr
Salvage-treatment phase
First
Second
Third or later
Previous allogeneic stem-cell transplantation
Yes
No
Bone marrow blasts
<50%
≥50%
Overall
Hazard Ratio (95% CI)Median Survival
Blinatumomab Chemotherapy
Subgroup
Prespecified Subgroup Analysis of Overall Survival
Prespecified Subgroup Analysis of Remission Rate
A
0.60 (0.35–1.03)
0.82 (0.61–1.10)
0.71 (0.55–0.93)
0.70 (0.51–0.96)
1.13 (0.64–1.99)
0.81 (0.51–1.29)
0.59 (0.38–0.91)
0.60 (0.39–0.91)
0.70 (0.46–1.06)
1.00.1
0.77 (0.55–1.08)
10.0
Blinatumomab
Better
Chemotherapy
Better
Age
<35 yr
≥35 yr
Salvage-treatment phase
First
Second
Third or later
Previous allogeneic stem-cell transplantation
Yes
No
Bone marrow blasts
<50%
≥50%
Overall
Blinatumomab Odds Ratio (95% CI)ChemotherapySubgroup
B
3.65 (1.63–8.17)
1.99 (1.12–3.55)
2.40 (1.51–3.80)
1.81 (1.06–3.09)
4.10 (1.11–15.12)
5.56 (2.02–15.36)
3.37 (1.35–8.38)
2.03 (1.08–3.80)
2.27 (1.15–4.50)
1.00.1
2.50 (1.34–4.66)
53/123 (43.1)
66/148 (44.6)
60/114 (52.6)
36/91 (39.6)  
23/66 (34.8)  
38/94 (40.4)  
81/177 (45.8)
55/84 (65.5)  
64/186 (34.4)
119/271 (43.9)  
15/60 (25.0)  
18/74 (24.3)  
23/65 (35.4)  
7/43 (16.3)
3/26 (11.5)
5/46 (10.9)
28/88 (31.8)  
13/38 (34.2)  
20/96 (20.8)  
33/134 (24.6)
no. of events/no. of patients (%)
  123
148
114
91
66
94
177
84
  18
  271
  9.9
  5.6
11.1
5.1
3.7
7.7
  7.7
11.5
  5.0
  7.7
mono. of patients
60
74
65
43
26
46
88
38
96
  134
4.5
3.8
5.3
3.3
3.0
5.3
3.7
6.8
3.7
  4.0
mono. of patients
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tumomab group and 4.6 months (95% CI, 1.8 to 
19.0) in the chemotherapy group. For the key 
secondary efficacy end point of event-free sur-
vival, 6-month estimates were 31% in the blina-
tumomab and 12% in the chemotherapy group, 
and the hazard ratio for a relapse after achieving 
a complete remission with full, partial, or incom-
plete hematologic recovery, or death, was 0.55 
(95% CI, 0.43 to 0.71; P<0.001) (Fig. 1C).
Allogeneic Stem-Cell Transplantation
A total of 24% of the patients in the blinatu-
momab group and 24% of the patients in the 
chemotherapy group underwent allogeneic stem-
cell transplantation, including 14% and 9% of 
patients, respectively, who achieved remission 
without the use of another treatment; 3% and 
4% of patients who achieved remission with the 
use of an intervening anticancer therapy; 1% of 
patients in each group who had a relapse after 
having achieved complete remission with full, 
partial, or incomplete hematologic recovery; and 
6% and 10% of patients who did not achieve 
complete remission with full, partial, or incom-
plete hematologic recovery. Among the patients 
who achieved complete remission with full, par-
tial, or incomplete hematologic recovery and who 
underwent allogeneic stem-cell transplantation, 
10 of 38 patients (26%) in the blinatumomab 
group and 3 of 12 patients (25%) in the chemo-
therapy group died during a median follow-up 
period of 206 and 279 days, respectively.
Adverse Events
Adverse events were reported in 99% of the 
patients in each treatment group (Table 3, and 
Table S4 in the Supplementary Appendix). Serious 
adverse events were reported in 62% of the patients 
in the blinatumomab group and in 45% in the 
chemotherapy group (Table 3, and Table S5 in the 
Supplementary Appendix). After adjustment for 
treatment exposure, the event rate for serious 
adverse events was 349.4 per 100 patient-years in 
the blinatumomab group and 641.9 per 100 patient-
years in the chemotherapy group. Fatal adverse 
events were reported in 19% of the patients in the 
blinatumomab group and in 17% of the patients 
in the chemotherapy group (Table 3). Fatal adverse 
events that occurred in at least 1% of the patients 
in either treatment group were sepsis (eight pa-
tients [3%] in the blinatumomab group and four 
patients [4%] in the chemotherapy group), septic 
shock (six patients [2%] and no patients, respec-
tively), multiorgan failure (three patients [1%] and 
no patients), respiratory failure (one patient [<1%] 
and two patients [2%]), and bacteremia (no pa-
tients and two patients [2%]). Investigators consid-
ered fatal adverse events to be related to treatment 
with blinatumomab or chemotherapy in eight 
patients (3%) and eight patients (7%), respectively.
Adverse events of grade 3 or higher were re-
ported in 87% of the patients in the blinatumo-
mab group and in 92% of the patients in the 
chemotherapy group (Table 3). The incidence of 
grade 3 or higher events of interest that were 
Response Category
Blinatumomab Group 
(N = 271)
Chemotherapy Group 
(N = 134)
Treatment Difference  
(95% CI)
P  
Value†
no. % (95% CI) no. % (95% CI) percentage points
Complete remission with full hemato‑
logic recovery
 91 33.6 (28.0–39.5) 21 15.7 (10.0–23.0) 17.9 (9.6–26.2) <0.001
Complete remission with full, partial, or 
incomplete hematologic recovery
119 43.9 (37.9–50.0) 33 24.6 (17.6–32.8) 19.3 (9.9–28.7) <0.001
Complete remission with partial hema‑
tologic recovery
 24 8.9 (5.8–12.9)  6 4.5 (1.7–9.5)
Complete remission with incomplete 
hematologic recovery
  4 1.5 (0.4–3.7)  6 4.5 (1.7–9.5)
*  Data are summarized for all patients who underwent randomization (intention‑to‑treat population). Complete remission was defined as 5% 
or less bone marrow blasts and no evidence of disease and was further characterized according to the extent of recovery of peripheral blood 
counts as follows: complete remission with full recovery (platelet count of >100,000 per microliter and absolute neutrophil count of >1000 
per microliter), complete remission with partial recovery (platelet count of >50,000 per microliter and absolute neutrophil count of >500 per 
microliter), or complete remission with incomplete recovery (platelet count of >100,000 per microliter or absolute neutrophil count of >1000 
per microliter).
†  Rates were compared with the use of a Cochran–Mantel–Haenszel test, with adjustment for the following stratification factors: age (<35 vs. 
≥35 years), previous salvage therapy (yes vs. no), and previous allogeneic stem‑cell transplantation (yes vs. no).
Table 2. Best Hematologic Response Within 12 Weeks after Treatment Initiation.*
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categorized as neutropenia or infection was lower 
with blinatumomab than with chemotherapy; in 
contrast, neurologic events of grade 3 or higher 
occurred at a similar rate in the two groups 
(Table 3, and Table S6 in the Supplementary Ap-
pendix). The rates of treatment discontinuation 
due to any adverse event were 12% in the blina-
tumomab group and 8% in the chemotherapy 
group, including 4% and 1%, respectively, due to 
a neurologic event and 1% and 0% due to the 
cytokine release syndrome. In the blinatumomab 
group, treatment interruptions were required, as 
specified in the protocol, for 32% of patients over-
all, including 7% for infections, 6% for neurologic 
events, 5% for the cytokine release syndrome, 3% 
for infusion reactions, and 3% for neutropenia. In 
the chemotherapy group, treatment interruptions 
were not required by the protocol but were re-
ported in 6% of patients. In the blinatumomab 
group, events of interest in the category of the 
cytokine release syndrome were reported as seri-
ous adverse events in 4% of the patients and as 
events of grade 3 or higher in 5% of the patients.
Discussion
In this randomized phase 3 trial involving adults 
with Ph-negative relapsed or refractory B-cell pre-
cursor ALL, blinatumomab resulted in significant-
ly longer overall survival than standard chemo-
therapy; the risk of death was 29% lower and the 
median duration of survival was 3.7 months 
longer in the blinatumomab group than in the 
chemotherapy group. Rates of complete remis-
sion with full hematologic recovery and complete 
remission with full, partial, or incomplete hema-
tologic recovery were significantly higher with 
blinatumomab therapy than with chemotherapy, 
and the median duration of remission was longer. 
Adverse events that occurred in the blinatumo-
mab group were consistent with those reported 
in previous trials. In single-group trials of blina-
tumomab,17,18 neurologic events and the cytokine 
release syndrome were identified as two adverse 
events of interest. In the current controlled trial, 
blinatumomab was associated with lower inci-
dences of myelosuppression and associated com-
plications than chemotherapy and was associated 
with higher incidences of serious adverse events, 
including neurologic events, the cytokine release 
syndrome, administration-site conditions, and 
procedural complications (Table S5 in the Sup-
plementary Appendix). After adjustment for dif-
ferences in treatment exposure between the two 
groups, the event rate for serious adverse events 
was lower overall in the blinatumomab group 
Event
Blinatumomab Group 
(N = 267)
Chemotherapy Group 
(N = 109)
no. of patients (%)
Any adverse event 263 (98.5) 108 (99.1)
Event leading to premature discontinuation of trial treatment 33 (12.4) 9 (8.3)
Serious adverse event 165 (61.8) 49 (45.0)
Fatal serious adverse event 51 (19.1) 19 (17.4)
Any adverse event of grade ≥3 231 (86.5) 100 (91.7)
Grade ≥3 adverse event of interest reported in at least 3%  
of patients in either group
Neutropenia 101 (37.8) 63 (57.8)
Infection 91 (34.1) 57 (52.3)
Elevated liver enzyme 34 (12.7) 16 (14.7)
Neurologic event 25 (9.4) 9 (8.3)
Cytokine release syndrome 13 (4.9) 0
Infusion reaction 9 (3.4) 1 (0.9)
Lymphopenia 4 (1.5) 4 (3.7)
Any decrease in platelet count 17 (6.4) 13 (11.9)
Any decrease in white‑cell count 14 (5.2) 6 (5.5)
*  Data are summarized for all patients who received at least one dose of trial treatment.
Table 3. Adverse Events.*
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than in the chemotherapy group. Rates of neuro-
logic events of grade 3 or higher were similar in 
the two groups. The cytokine release syndrome 
was reported in the blinatumomab group but 
usually did not require discontinuation of blina-
tumomab treatment. On the basis of efficacy and 
safety results from the planned interim analysis, 
the independent data and safety monitoring com-
mittee recommended that the trial be stopped 
early because of the overall survival benefit ob-
served with blinatumomab as compared with 
chemotherapy. In an analysis of patient-reported 
outcomes in this trial that was reported separate-
ly,23 health-related quality of life, patient function, 
and symptoms associated with blinatumomab as 
compared with chemotherapy were examined. 
In that analysis, the global health status and 
quality-of-life score improved in the blinatumo-
mab group and worsened in the chemotherapy 
group, with a hazard ratio for deterioration in a 
time-to-event analysis of 0.67 (95% CI, 0.52 to 
0.87). Hazard ratios for other quality-of-life out-
comes ranged from 0.59 to 0.80 in favor of 
blinatumomab, with upper boundaries of the 
95% confidence intervals that were less than 1.0 
across all subscales and single items except for 
insomnia (95% CI, 0.62 to 1.02).
Several surface antigens are expressed on B-cell 
precursor ALL blasts, which allows for the use 
of targeted therapies.24-26 CD20 is expressed on 
B-cell precursor leukemic cells in up to 50% of 
patients.13,27 Rituximab, an unconjugated CD20 
monoclonal antibody, had minimal efficacy in 
the treatment of B-cell precursor ALL, but its 
addition to intensive chemotherapy was associ-
ated with longer survival in both Burkitt’s leuke-
mia and CD20-positive B-cell precursor ALL than 
was intensive chemotherapy alone.28-32 CD22 is ex-
pressed in more than 90% of patients with B-cell 
ALL. Among patients with relapsed or refrac-
tory ALL, treatment with inotuzumab ozogami-
cin (a CD22 monoclonal antibody conjugated to 
calicheamicin) resulted in higher rates of com-
plete remission and higher rates of negative mini-
mal residual disease than the rates seen with 
chemotherapy.33-35 Overall survival, a primary end 
point of the trial, was not significantly longer 
with inotuzumab than with chemotherapy at the 
prespecified boundary of P = 0.0208. Treatment 
with chimeric antigen receptor T cells that target 
CD19 was associated with complete remission 
rates of 70 to 90% and durable remissions in 
single-center trials involving patients who had 
minimal residual disease or overt relapse.36-38 
Combinations of targeted therapies have not 
been investigated.
This trial of blinatumomab versus chemo-
therapy differs in several ways from a recently 
reported trial of inotuzumab versus chemothera-
py in relapsed or refractory B-cell precursor ALL.35 
The median overall survival was 7.7 months in 
the experimental group in both trials, but when 
similar chemotherapy regimens were adminis-
tered, the median survival was 4.0 months in the 
current trial and 6.7 months in the inotuzumab 
trial, which suggests that the patient population 
in this trial had more aggressive disease than 
the population in the inotuzumab trial. Indeed, 
one in four patients in our trial received blinatu-
momab as third or later salvage therapy, whereas 
such patients were excluded from participation 
in the inotuzumab trial. No patient in the blina-
tumomab trial and 43% of inotuzumab-treated 
patients had a late first relapse (≥12 months 
after initial remission). Patients with high periph-
eral blasts (>10,000 per microliter) at baseline 
were permitted to receive blinatumomab in this 
trial but could not receive inotuzumab in the 
other trial. The percentage of patients who had 
undergone previous allogeneic stem-cell trans-
plantation was 35% in this trial and 16% for 
inotuzumab-treated patients. The inotuzumab trial 
included patients with Ph-positive ALL, whereas 
this trial did not. Collectively, these differences 
suggest that patients were at greater risk of 
death and complications in this trial than in the 
inotuzumab trial. Thus, the efficacy results for 
blinatumomab and inotuzumab should not be 
compared across trials. However, both trials 
highlight the potential for directed therapies for 
patients with relapsed or refractory B-cell pre-
cursor ALL to reduce the need for prolonged, 
intensive chemotherapy.
Patients in the blinatumomab group who 
achieved complete remission with full, partial, 
or incomplete hematologic recovery had a higher 
incidence of response with respect to minimal 
residual disease than did patients in the chemo-
therapy group, which highlighted the depth and 
quality of remissions achieved with blinatumo-
mab. Although minimal residual disease status 
during a patient’s first complete remission has 
emerged as the most important prognostic fac-
tor in the initial treatment of ALL in children and 
adults,39,40 its value as a prognostic factor in re-
lapsed or refractory ALL is less well established. 
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In this trial, the use of two central laboratories 
with different methods for assessing minimal 
residual disease may have introduced a variable 
that could limit interpretation of the trial. Never-
theless, the introduction of targeted immuno-
therapy for patients who remain positive for 
minimal residual disease during their first com-
plete remission may improve the prognosis of 
such patients.
In summary, this large, randomized trial of 
single-agent immunotherapy with blinatumomab 
shows a significant survival benefit as compared 
with chemotherapy in adults with Ph-negative re-
lapsed or refractory ALL. Blinatumomab resulted 
in significantly higher rates of hematologic re-
mission and longer survival than chemotherapy. 
Given the previous exposure of these patients to 
myelosuppressive and immunosuppressive treat-
ments, the activity of an immune-based therapy 
such as blinatumomab, which depends on func-
tioning T cells for its activity, provides encour-
agement that responses may be further enhanced 
and made durable with additional immune acti-
vation strategies.
Supported by Amgen.
Dr. Kantarjian reports receiving grant support from Amgen, 
Pfizer, Bristol-Myers Squibb, Novartis Pharmaceuticals, and 
Ariad Pharmaceuticals; Dr. Stein, receiving lecture fees from 
Amgen; Dr. Gökbuget, serving on an advisory board for Kite 
Pharma (uncompensated), receiving fees for serving on advisory 
boards from Amgen, Pfizer, and Celgene/Juno Therapeutics, 
travel support from Amgen and Pfizer, and grant support from 
Amgen; Dr. Fielding, receiving fees for lectures and serving on 
an advisory board from Amgen; Dr. Schuh, receiving fees for 
serving on an advisory board from Amgen; Dr. Wei, receiving 
fees for serving on an advisory board and grant support from 
Amgen; Dr. Dombret, receiving honoraria from Roche/Genen-
tech, Amgen, Pfizer, Ariad Pharmaceuticals, Novartis Pharma-
ceuticals, Celgene, Jazz Pharmaceuticals, Agios Pharmaceuticals, 
Sunesis Pharmaceuticals, Ambit Biosciences (now Daiichi-
Sankyo), Karyopharm Therapeutics, Kite Pharma, Menarini, 
Astellas, Janssen, Servier, and Seattle Genetics, consulting fees 
from Amgen and Celgene, and grant support from Roche/ 
Genentech, Amgen, Ariad Pharmaceuticals, Jazz Pharmaceuti-
cals, and Kite Pharma; Dr. Foà, receiving fees for serving on 
advisory boards from Roche, Genentech, Janssen, Celgene, Ariad 
Pharmaceuticals, and Amgen, and lecture fees from Roche, Genen-
tech, Janssen, Gilead Sciences, Celgene, Novartis Pharmaceuti-
cals, and Sandoz; Dr. Bassan, receiving fees for consulting and 
serving on advisory boards from Amgen; Dr. Arslan, receiving 
fees for serving on an advisory board from Amgen; Dr. Ram-
baldi, receiving lecture fees and travel support from Amgen; Dr. 
Horst, receiving study fees from Sunesis Pharmaceuticals and 
Boehringer Ingelheim; Dr. Brüggemann, receiving fees for serving 
on advisory boards from Incyte and Amgen, lecture fees from 
Roche and Amgen, grant support from Amgen, and financial 
support for reference diagnostics from Affimed, Regeneron 
Pharmaceuticals, and Amgen; Dr. Klapper, receiving grant sup-
port to his institution from Roche, Novartis Pharmaceuticals, 
Regeneron Pharmaceuticals, and Janssen; Dr. Wood, receiving 
honoraria from Amgen and Seattle Genetics and holding labora-
tory service agreements with Pfizer, Juno Therapeutics, and Seat-
tle Genetics; Mr. Fleishman, Dr. Nagorsen, Mr. Holland, and Dr. 
Zimmerman, being employees of and holding stock in Amgen; 
Mr. Holland, also holding stock in MacroGenics; and Dr. Topp, 
receiving fees for serving on advisory boards from Amgen, Re-
generon Pharmaceuticals, Affimed, Jazz Pharmaceuticals, Gilead 
Sciences, and Pfizer and travel support from Amgen, Roche, 
Regeneron Pharmaceuticals, and Affimed. No other potential 
conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank Robert Dawson of CACTUS Communications for 
graphics support, funded by Amgen; and Geoffrey Smith of Am-
gen and Jonathan Latham for medical writing support, funded 
by Amgen.
Appendix
The authors’ affiliations are as follows: the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston 
(H.K.); City of Hope National Medical Center, Duarte (A.S.), and Amgen, Thousand Oaks (A.F., D.N., Z.Z.) — both in California; 
Goethe University, University Hospital, Department of Medicine II, Frankfurt am Main (N.G.), Medical Department II (H.-A.H., M.B.) 
and Hematopathology Section and Lymph Node Registry (W.K.), University Hospital Schleswig Holstein, Campus Kiel, Kiel, and Med-
izinische Klinik und Poliklinik II, Universitätsklinikums Würzburg, Würzburg (M.S.T.) — all in Germany; Royal Free Hospital and 
University College London Cancer Institute, London (A.K.F.); Princess Margaret Cancer Centre, Toronto (A.C.S.), and Centre Intégré 
Universitaire de Santé et de Services Sociaux de l’est de l’île de Montréal, Hôpital Maisonneuve-Rosemont, Montreal (J.B.) — all in 
Canada; ICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Universitat Autonoma de Barcelona, Barce-
lona (J.-M.R.), the Department of Medicine, Hospital Universitari i Politecnic La Fe, University of Valencia, Valencia, and Centro de 
Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid (M.A.S.) — all in Spain; Alfred Hospital and Monash Univer-
sity, Melbourne, VIC, Australia (A.W.); Institut Universitaire d’Hématologie, Hôpital Saint-Louis (Assistance Publique – Hôpitaux de 
Paris), Paris (H.D.), and Centre Hospitalier Lyon Sud, Pierre-Benite (X.T.) — both in France; Ematologia, Dipartimento di Biotecnologie 
Cellulari ed Ematologia, Azienda Ospedaliera Policlinico Umberto I, Università Sapienza di Roma, Rome (R.F.), Azienda Unità Locale 
Socio Sanitaria 12 Veneziana Ospedale Dell Angelo, Venice (R.B.), and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Ber-
gamo, Università Statale di Milano, Milan (A.R.) — all in Italy; Ankara Universitesi, Tip Fakültesi, Cebeci Arastirma ve Uygulama Has-
tanesi, Ankara (Ö.A.), and Dokuz Eylül Üniversitesi Tıp Fakültesi, İzmir (F.D.) — both in Turkey; Instytut Hematologii i Transfuzjologii 
and Centrum Medyczne Kształcenia Podyplomowego, Warsaw, Poland (E.L.-M.); University of Washington Medical Center, Seattle 
(B.L.W.); and Amgen, Washington, DC (C.H.).
References
1. Jabbour E, O’Brien S, Konopleva M, 
Kantarjian H. New insights into the patho-
physiology and therapy of adult acute lym-
phoblastic leukemia. Cancer 2015; 121: 
2517-28.
2. Bassan R, Hoelzer D. Modern therapy 
of acute lymphoblastic leukemia. J Clin 
Oncol 2011; 29: 532-43.
3. Kantarjian H, Thomas D, O’Brien S, 
The New England Journal of Medicine 
Downloaded from nejm.org at SBBL on March 9, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
n engl j med 376;9 nejm.org March 2, 2017 847
Blinatumomab vs. Chemother apy for Advanced ALL
et al. Long-term follow-up results of hy-
perfractionated cyclophosphamide, vin-
cristine, doxorubicin, and dexamethasone 
(Hyper-CVAD), a dose-intensive regimen, 
in adult acute lymphocytic leukemia. Can-
cer 2004; 101: 2788-801.
4. Gökbuget N, Hoelzer D, Arnold R, et 
al. Treatment of adult ALL according to 
protocols of the German Multicenter 
Study Group for Adult ALL (GMALL). He-
matol Oncol Clin North Am 2000; 14: 
1307-25.
5. Tavernier E, Boiron JM, Huguet F, et al. 
Outcome of treatment after first relapse 
in adults with acute lymphoblastic leuke-
mia initially treated by the LALA-94 trial. 
Leukemia 2007; 21: 1907-14.
6. Oriol A, Vives S, Hernández-Rivas JM, 
et al. Outcome after relapse of acute lym-
phoblastic leukemia in adult patients in-
cluded in four consecutive risk-adapted 
trials by the PETHEMA Study Group. Hae-
matologica 2010; 95: 589-96.
7. Thomas DA, Kantarjian H, Smith TL, 
et al. Primary refractory and relapsed 
adult acute lymphoblastic leukemia: char-
acteristics, treatment results, and prog-
nosis with salvage therapy. Cancer 1999; 
86: 1216-30.
8. Kantarjian HM, Thomas D, Ravandi F, 
et al. Defining the course and prognosis 
of adults with acute lymphocytic leuke-
mia in first salvage after induction failure 
or short first remission duration. Cancer 
2010; 116: 5568-74.
9. O’Brien S, Thomas D, Ravandi F, et al. 
Outcome of adults with acute lymphocytic 
leukemia after second salvage therapy. 
Cancer 2008; 113: 3186-91.
10. Gökbuget N, Stanze D, Beck J, et al. 
Outcome of relapsed adult lymphoblastic 
leukemia depends on response to salvage 
chemotherapy, prognostic factors, and 
performance of stem cell transplantation. 
Blood 2012; 120: 2032-41.
11. Gökbuget N, Hoelzer D. Salvage ther-
apy of adult acute lymphoblastic leuke-
mia. In: Faderl S, Kantarjian H, eds. Leu-
kemias: principles and practice of therapy. 
Oxford, United Kingdom: Wiley-Black-
well, 2011: 217-27.
12. Fielding AK, Richards SM, Chopra R, 
et al. Outcome of 609 adults after relapse 
of acute lymphoblastic leukemia (ALL); an 
MRC UKALL12/ECOG 2993 study. Blood 
2007; 109: 944-50.
13. Raponi S, De Propris MS, Intoppa S, 
et al. Flow cytometric study of potential 
target antigens (CD19, CD20, CD22, CD33) 
for antibody-based immunotherapy in 
acute lymphoblastic leukemia: analysis 
of 552 cases. Leuk Lymphoma 2011; 52: 
1098-107.
14. Löffler A, Gruen M, Wuchter C, et al. 
Efficient elimination of chronic lympho-
cytic leukaemia B cells by autologous T cells 
with a bispecific anti-CD19/anti-CD3 sin-
gle-chain antibody construct. Leukemia 
2003; 17: 900-9.
15. Dreier T, Lorenczewski G, Brandl C, 
et al. Extremely potent, rapid and co-
stimulation-independent cytotoxic T-cell 
response against lymphoma cells cata-
lyzed by a single-chain bispecific anti-
body. Int J Cancer 2002; 100: 690-7.
16. Hoffmann P, Hofmeister R, Brisch-
wein K, et al. Serial killing of tumor cells 
by cytotoxic T cells redirected with a 
CD19-/CD3-bispecific single-chain anti-
body construct. Int J Cancer 2005; 115: 98-
104.
17. Topp MS, Gökbuget N, Zugmaier G, 
et al. Phase II trial of the anti-CD19 bispe-
cific T cell-engager blinatumomab shows 
hematologic and molecular remissions 
in patients with relapsed or refractory 
B-precursor acute lymphoblastic leukemia. 
J Clin Oncol 2014; 32: 4134-40.
18. Topp MS, Gökbuget N, Stein AS, et al. 
Safety and activity of blinatumomab for 
adult patients with relapsed or refractory 
B-precursor acute lymphoblastic leukae-
mia: a multicentre, single-arm, phase 2 
study. Lancet Oncol 2015; 16: 57-66.
19. Brüggemann M, Schrauder A, Raff T, 
et al. Standardized MRD quantification in 
European ALL trials: proceedings of the 
Second International Symposium on MRD 
assessment in Kiel, Germany, 18-20 Sep-
tember 2008. Leukemia 2010; 24: 521-35.
20. Borowitz MJ, Wood BL, Devidas M, et 
al. Prognostic significance of minimal 
residual disease in high risk B-ALL: a re-
port from Children’s Oncology Group 
study AALL0232. Blood 2015; 126: 964-71.
21. O’Brien PC, Fleming TR. A multiple 
testing procedure for clinical trials. Bio-
metrics 1979; 35: 549-56.
22. Lan KKG, DeMets DL. Discrete se-
quential boundaries for clinical trials. 
Biometrika 1983; 70: 659-63.
23. Topp M, Zimmerman Z, Cannell P, et 
al. Health-related quality of life (HRQoL) 
of blinatumomab versus standard of care 
(SOC) chemotherapy in patients with re-
lapsed or refractory Philadelphia negative 
B-cell precursor acute lymphoblastic leu-
kemia in a randomized, open-label phase 3 
study (TOWER). Blood 2016; 128: 222. ab-
stract.
24. Jabbour E, O’Brien S, Ravandi F, Kan-
tarjian H. Monoclonal antibodies in acute 
lymphoblastic leukemia. Blood 2015; 125: 
4010-6.
25. Hoelzer D, Gökbuget N. Chemoimmu-
notherapy in acute lymphoblastic leuke-
mia. Blood Rev 2012; 26: 25-32.
26. Kantarjian H, Thomas D, Wayne AS, 
O’Brien S. Monoclonal antibody-based 
therapies: a new dawn in the treatment 
of acute lymphoblastic leukemia. J Clin 
Oncol 2012; 30: 3876-83.
27. Thomas DA, O’Brien S, Jorgensen JL, 
et al. Prognostic significance of CD20 ex-
pression in adults with de novo precursor 
B-lineage acute lymphoblastic leukemia. 
Blood 2009; 113: 6330-7.
28. Thomas DA, Faderl S, O’Brien S, et al. 
Chemoimmunotherapy with hyper-CVAD 
plus rituximab for the treatment of adult 
Burkitt and Burkitt-type lymphoma or 
acute lymphoblastic leukemia. Cancer 
2006; 106: 1569-80.
29. Thomas DA, O’Brien S, Faderl S, et al. 
Chemoimmunotherapy with a modified 
hyper-CVAD and rituximab regimen im-
proves outcome in de novo Philadelphia 
chromosome-negative precursor B-lineage 
acute lymphoblastic leukemia. J Clin On-
col 2010; 28: 3880-9.
30. Ribrag V, Koscielny S, Bosq J, et al. 
Rituximab and dose-dense chemotherapy 
for adults with Burkitt’s lymphoma: a ran-
domised, controlled, open-label, phase 3 
trial. Lancet 2016; 387: 2402-11.
31. Maury S, Chevret S, Thomas X, et al. 
Rituximab in B-lineage adult acute lym-
phoblastic leukemia. N Engl J Med 2016; 
375: 1044-53.
32. Jabbour E, Kantarjian H. Chemoim-
munotherapy as a new standard of care 
for Burkitt leukaemia/lymphoma. Lancet 
2016; 387: 2360-1.
33. Kantarjian H, Thomas D, Jorgensen J, 
et al. Inotuzumab ozogamicin, an anti-
CD22-calecheamicin conjugate, for refrac-
tory and relapsed acute lymphocytic leu-
kaemia: a phase 2 study. Lancet Oncol 
2012; 13: 403-11.
34. Kantarjian H, Thomas D, Jorgensen J, 
et al. Results of inotuzumab ozogamicin, 
a CD22 monoclonal antibody, in refractory 
and relapsed acute lymphocytic leukemia. 
Cancer 2013; 119: 2728-36.
35. Kantarjian HM, DeAngelo DJ, Stelljes 
M, et al. Inotuzumab ozogamicin versus 
standard therapy for acute lymphoblastic 
leukemia. N Engl J Med 2016; 375: 740-53.
36. Maude SL, Frey N, Shaw PA, et al. Chi-
meric antigen receptor T cells for sus-
tained remissions in leukemia. N Engl J 
Med 2014; 371: 1507-17.
37. Davila ML, Riviere I, Wang X, et al. 
Efficacy and toxicity management of 19-28z 
CAR T cell therapy in B cell acute lympho-
blastic leukemia. Sci Transl Med 2014; 6: 
224ra25.
38. Lee DW, Kochenderfer JN, Stetler-
Stevenson M, et al. T cells expressing 
CD19 chimeric antigen receptors for 
acute lymphoblastic leukaemia in chil-
dren and young adults: a phase 1 dose-
escalation trial. Lancet 2015; 385: 517-28.
39. Gökbuget N, Kneba M, Raff T, et al. 
Adult patients with acute lymphoblastic 
leukemia and molecular failure display a 
poor prognosis and are candidates for 
stem cell transplantation and targeted 
therapies. Blood 2012; 120: 1868-76.
40. Goekbuget N, Dombret H, Bonifacio M, 
et al. BLAST: A confirmatory, single-arm, 
phase 2 study of blinatumomab, a bispe-
cific T-cell engager (BiTE®) antibody con-
struct, in patients with minimal residual 
disease B-precursor acute lymphoblastic 
leukemia (ALL). Blood 2014; 124: 379. ab-
stract.
Copyright © 2017 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at SBBL on March 9, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
